Didn’t have time to read all of the business highlights in San Diego this week? You’re in luck! Your high level dose of some of the top headlines in San Diego business and innovation is here.
- Illumina, the Google of Genetic Testing, Has Plans for World Domination: You could say that Illumina is to DNA sequencing is what Google is to Internet search, but that would be underselling the San Diego-based biotech company. Illumina’s machines, the best and cheapest on the market, generate 90 percent of all DNA sequence data today. Illumina is, as they say, crushing it. Read more
- Pfizer Donates $5 Million to La Jolla Institute of Allergy and Immunology: Pharmaceutical giant Pfizer has donated $5 million to the La Jolla Institute for Allergy and Immunology, much of which will be used to create an endowed chair in cancer immunology. The gift is the largest private donation ever received by LJI, which has struggled to supplement federal and industry funding with philanthropy. Read more
- Congrats to LJI’s President and Chief Scientific Officer, Mitchell Kronenberg, Ph.D., who was recently awarded Most Admired CEO of the Year Award by San Diego Business Journal in the Large Non-Profit Organization Category!
- SDSU to Host Kyoto Prize Winner Toyoki Kunitake: Pioneering chemist Toyoki Kunitake will come to San Diego next month, it was announced Monday. Kunitake, who received the 2015 Kyoto Prize — Japan’s highest private award for global achievement — in the area of “Advanced Technology,” will speak at San Diego State University at 10 a.m. March 16. Read more
- Wrike, SaaS company, Announces San Diego As New Office Location and Provides 150 Jobs: Wrike, the Mountain View, California-based developer of enterprise work management software, announced the opening of a new office in San Diego with plans to create 150 jobs over the next three years in sales and customer service. Read more
- San Diego Social Media Management Startup Soci Adds $2.5M to Round: Soci, a social media content and marketing company that raised $1.5 million in late 2014, has raised an additional $2.5 million for its Series A Round, mostly from individual investors. Read more
- Pfizer Receives Expanded FDA Approval For IBRANCE (palbociclib) In HR+, HER2- Metastatic Breast Cancer: Last month, Pfizer announced that the U.S. Food and Drug Administration (FDA) has approved a new indication expanding the use of IBRANCE® (palbociclib) 125mg capsules, Pfizer’s metastatic breast cancer therapy. Read more
Want to see these types of news roundups each week in your inbox? Click here to sign up for CONNECT’s weekly e-newsletter!